Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1995 Jun;63(6):2100–2108. doi: 10.1128/iai.63.6.2100-2108.1995

A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins.

M Roberts 1, A Bacon 1, R Rappuoli 1, M Pizza 1, I Cropley 1, G Douce 1, G Dougan 1, M Marinaro 1, J McGhee 1, S Chatfield 1
PMCID: PMC173272  PMID: 7768587

Abstract

We examined the capacity of a genetically detoxified derivative of pertussis toxin (PTX), PT-9K/129G, to act as a mucosal adjuvant for an intranasally (i.n.) administered tetanus vaccine. Groups of mice were immunized i.n. with the nontoxic C-terminal 50-kDa portion of tetanus toxin (fragment C [Frg C]) either alone or mixed with PT-9K/129G, PTX, or cholera toxin (CT) or were immunized subcutaneously (s.c.) with an equivalent amount of Frg C adsorbed to alhydrogel. In response to a single immunization, mice receiving Frg C plus PT-9K/129G or CT i.n. and parenterally immunized mice developed high-titer (> 20,000) anti-Frg C antibodies, whereas mice immunized i.n. with Frg C plus PTX or with Frg C alone seroconverted only after being boosted. The serum anti-Frg C response was dominated by immunoglobulin G1 (IgG1) in mice immunized with Frg C plus PT-9K/129G, with Frg C plus PTX, or s.c. In contrast, IgG1, IgG2a, and IgG2b contributed almost equally to the Frg C response when CT was the adjuvant. Anti-Frg C IgE was detected only in the sera of mice immunized i.n. with Frg C plus PTX and immunized s.c. with Frg C plus alhydrogel. High levels of IgA antibodies were present in nasal lavage fluid from mice immunized i.n. with Frg C plus PT-9K/129G, PTX, or CT but not in that from mice given Frg C alone i.n. or parenterally. The mucosal adjuvanticity of PT-9K/129G was manifested in inbred as well as outbred mice. A single i.n. dose of Frg C plus either PT-9K/129G or PTX (with high specific activity) was sufficient to protect all immunized mice from tetanus toxin challenge, in contrast to the case for mice that received Frg C alone i.n. We conclude that the pertussis toxin analog PT-9K/129G, which is devoid of ADP-ribosyltransferase activity, is a potent mucosal adjuvant for vaccines delivered via the respiratory tract.

Full Text

The Full Text of this article is available as a PDF (454.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Black W. J., Munoz J. J., Peacock M. G., Schad P. A., Cowell J. L., Burchall J. J., Lim M., Kent A., Steinman L., Falkow S. ADP-ribosyltransferase activity of pertussis toxin and immunomodulation by Bordetella pertussis. Science. 1988 Apr 29;240(4852):656–659. doi: 10.1126/science.2896387. [DOI] [PubMed] [Google Scholar]
  2. Clare J. J., Rayment F. B., Ballantine S. P., Sreekrishna K., Romanos M. A. High-level expression of tetanus toxin fragment C in Pichia pastoris strains containing multiple tandem integrations of the gene. Biotechnology (N Y) 1991 May;9(5):455–460. doi: 10.1038/nbt0591-455. [DOI] [PubMed] [Google Scholar]
  3. Clements J. D., Hartzog N. M., Lyon F. L. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine. 1988 Jun;6(3):269–277. doi: 10.1016/0264-410x(88)90223-x. [DOI] [PubMed] [Google Scholar]
  4. Fairweather N. F., Lyness V. A., Maskell D. J. Immunization of mice against tetanus with fragments of tetanus toxin synthesized in Escherichia coli. Infect Immun. 1987 Nov;55(11):2541–2545. doi: 10.1128/iai.55.11.2541-2545.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gizurarson S., Tamura S., Aizawa C., Kurata T. Stimulation of the transepithelial flux of influenza HA vaccine by cholera toxin B subunit. Vaccine. 1992;10(2):101–106. doi: 10.1016/0264-410x(92)90025-f. [DOI] [PubMed] [Google Scholar]
  6. Gizurarson S., Tamura S., Kurata T., Hasiguchi K., Ogawa H. The effect of cholera toxin and cholera toxin B subunit on the nasal mucosal membrane. Vaccine. 1991 Nov;9(11):825–832. doi: 10.1016/0264-410x(91)90220-z. [DOI] [PubMed] [Google Scholar]
  7. Halpern J. L., Loftus A. Characterization of the receptor-binding domain of tetanus toxin. J Biol Chem. 1993 May 25;268(15):11188–11192. [PubMed] [Google Scholar]
  8. Hirabayashi Y., Kurata H., Funato H., Nagamine T., Aizawa C., Tamura S., Shimada K., Kurata T. Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination. Vaccine. 1990 Jun;8(3):243–248. doi: 10.1016/0264-410x(90)90053-o. [DOI] [PubMed] [Google Scholar]
  9. Holmgren J., Czerkinsky C., Lycke N., Svennerholm A. M. Mucosal immunity: implications for vaccine development. Immunobiology. 1992 Feb;184(2-3):157–179. doi: 10.1016/S0171-2985(11)80473-0. [DOI] [PubMed] [Google Scholar]
  10. Holmgren J., Lycke N., Czerkinsky C. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. Vaccine. 1993 Sep;11(12):1179–1184. doi: 10.1016/0264-410x(93)90039-z. [DOI] [PubMed] [Google Scholar]
  11. Hörnquist E., Lycke N. Cholera toxin adjuvant greatly promotes antigen priming of T cells. Eur J Immunol. 1993 Sep;23(9):2136–2143. doi: 10.1002/eji.1830230914. [DOI] [PubMed] [Google Scholar]
  12. Illum L. The nasal delivery of peptides and proteins. Trends Biotechnol. 1991 Aug;9(8):284–289. doi: 10.1016/0167-7799(91)90091-u. [DOI] [PubMed] [Google Scholar]
  13. Kolb J. P., Genot E., Petit-Koskas E., Paul-Eugene N., Dugas B. Effect of bacterial toxins on human B cell activation. I. Mitogenic activity of pertussis toxin. Eur J Immunol. 1990 May;20(5):969–976. doi: 10.1002/eji.1830200504. [DOI] [PubMed] [Google Scholar]
  14. Levine M. M., Kaper J. B., Black R. E., Clements M. L. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol Rev. 1983 Dec;47(4):510–550. doi: 10.1128/mr.47.4.510-550.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lycke N., Holmgren J. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology. 1986 Oct;59(2):301–308. [PMC free article] [PubMed] [Google Scholar]
  16. Lycke N., Tsuji T., Holmgren J. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur J Immunol. 1992 Sep;22(9):2277–2281. doi: 10.1002/eji.1830220915. [DOI] [PubMed] [Google Scholar]
  17. McGhee J. R., Mestecky J., Dertzbaugh M. T., Eldridge J. H., Hirasawa M., Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine. 1992;10(2):75–88. doi: 10.1016/0264-410x(92)90021-b. [DOI] [PubMed] [Google Scholar]
  18. Nencioni L., Pizza M. G., Volpini G., De Magistris M. T., Giovannoni F., Rappuoli R. Properties of the B oligomer of pertussis toxin. Infect Immun. 1991 Dec;59(12):4732–4734. doi: 10.1128/iai.59.12.4732-4734.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Nencioni L., Pizza M., Bugnoli M., De Magistris T., Di Tommaso A., Giovannoni F., Manetti R., Marsili I., Matteucci G., Nucci D. Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough. Infect Immun. 1990 May;58(5):1308–1315. doi: 10.1128/iai.58.5.1308-1315.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Nencioni L., Volpini G., Peppoloni S., Bugnoli M., De Magistris T., Marsili I., Rappuoli R. Properties of pertussis toxin mutant PT-9K/129G after formaldehyde treatment. Infect Immun. 1991 Feb;59(2):625–630. doi: 10.1128/iai.59.2.625-630.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Ovary Z., Caiazza S. S., Kojima S. PCA reactions with mouse antibodies in mice and rats. Int Arch Allergy Appl Immunol. 1975;48(1):16–21. doi: 10.1159/000231289. [DOI] [PubMed] [Google Scholar]
  22. Pizza M., Covacci A., Bartoloni A., Perugini M., Nencioni L., De Magistris M. T., Villa L., Nucci D., Manetti R., Bugnoli M. Mutants of pertussis toxin suitable for vaccine development. Science. 1989 Oct 27;246(4929):497–500. doi: 10.1126/science.2683073. [DOI] [PubMed] [Google Scholar]
  23. Podda A., Nencioni L., De Magistris M. T., Di Tommaso A., Bossù P., Nuti S., Pileri P., Peppoloni S., Bugnoli M., Ruggiero P. Metabolic, humoral, and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT-9K/129G. J Exp Med. 1990 Sep 1;172(3):861–868. doi: 10.1084/jem.172.3.861. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Rappuoli R., Pizza M., Covacci A., Bartoloni A., Nencioni L., Podda A., De Magistris M. T. Recombinant acellular pertussis vaccine--from the laboratory to the clinic: improving the quality of the immune response. FEMS Microbiol Immunol. 1992 Oct;5(4):161–170. doi: 10.1111/j.1574-6968.1992.tb05898.x. [DOI] [PubMed] [Google Scholar]
  25. Reuman P. D., Keely S. P., Schiff G. M. Similar subclass antibody responses after intranasal immunization with UV-inactivated RSV mixed with cholera toxin or live RSV. J Med Virol. 1991 Nov;35(3):192–197. doi: 10.1002/jmv.1890350309. [DOI] [PubMed] [Google Scholar]
  26. Snider D. P., Marshall J. S., Perdue M. H., Liang H. Production of IgE antibody and allergic sensitization of intestinal and peripheral tissues after oral immunization with protein Ag and cholera toxin. J Immunol. 1994 Jul 15;153(2):647–657. [PubMed] [Google Scholar]
  27. Spangler B. D. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol Rev. 1992 Dec;56(4):622–647. doi: 10.1128/mr.56.4.622-647.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Stanfield J. P., Galazka A. Neonatal tetanus in the world today. Bull World Health Organ. 1984;62(4):647–669. [PMC free article] [PubMed] [Google Scholar]
  29. Tamura M., Nogimori K., Murai S., Yajima M., Ito K., Katada T., Ui M., Ishii S. Subunit structure of islet-activating protein, pertussis toxin, in conformity with the A-B model. Biochemistry. 1982 Oct 26;21(22):5516–5522. doi: 10.1021/bi00265a021. [DOI] [PubMed] [Google Scholar]
  30. Tamura S., Shoji Y., Hasiguchi K., Aizawa C., Kurata T. Effects of cholera toxin adjuvant on IgE antibody response to orally or nasally administered ovalbumin. Vaccine. 1994 Oct;12(13):1238–1240. doi: 10.1016/0264-410x(94)90250-x. [DOI] [PubMed] [Google Scholar]
  31. Tamura S., Yamanaka A., Shimohara M., Tomita T., Komase K., Tsuda Y., Suzuki Y., Nagamine T., Kawahara K., Danbara H. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine. Vaccine. 1994 Apr;12(5):419–426. doi: 10.1016/0264-410x(94)90118-x. [DOI] [PubMed] [Google Scholar]
  32. Torrigiani G. Quantitative estimation of antibodies in the immunoglobulin classes of the mouse. I. Effect of adjuvants on the antibody response to human serum albumin and keyhole limpet haemocyanin. Clin Exp Immunol. 1972 May;11(1):125–135. [PMC free article] [PubMed] [Google Scholar]
  33. Wardlaw A. C., Parton R. Bordetella pertussis toxins. Pharmacol Ther. 1982;19(1):1–53. doi: 10.1016/0163-7258(82)90041-9. [DOI] [PubMed] [Google Scholar]
  34. Weiss A. A., Hewlett E. L. Virulence factors of Bordetella pertussis. Annu Rev Microbiol. 1986;40:661–686. doi: 10.1146/annurev.mi.40.100186.003305. [DOI] [PubMed] [Google Scholar]
  35. Wilson A. D., Bailey M., Williams N. A., Stokes C. R. The in vitro production of cytokines by mucosal lymphocytes immunized by oral administration of keyhole limpet hemocyanin using cholera toxin as an adjuvant. Eur J Immunol. 1991 Oct;21(10):2333–2339. doi: 10.1002/eji.1830211007. [DOI] [PubMed] [Google Scholar]
  36. Wilson A. D., Clarke C. J., Stokes C. R. Whole cholera toxin and B subunit act synergistically as an adjuvant for the mucosal immune response of mice to keyhole limpet haemocyanin. Scand J Immunol. 1990 Apr;31(4):443–451. doi: 10.1111/j.1365-3083.1990.tb02791.x. [DOI] [PubMed] [Google Scholar]
  37. Woogen S. D., Ealding W., Elson C. O. Inhibition of murine lymphocyte proliferation by the B subunit of cholera toxin. J Immunol. 1987 Dec 1;139(11):3764–3770. [PubMed] [Google Scholar]
  38. Wu H. Y., Russell M. W. Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit. Infect Immun. 1993 Jan;61(1):314–322. doi: 10.1128/iai.61.1.314-322.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Xu-Amano J., Kiyono H., Jackson R. J., Staats H. F., Fujihashi K., Burrows P. D., Elson C. O., Pillai S., McGhee J. R. Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. J Exp Med. 1993 Oct 1;178(4):1309–1320. doi: 10.1084/jem.178.4.1309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. de Aizpurua H. J., Russell-Jones G. J. Oral vaccination. Identification of classes of proteins that provoke an immune response upon oral feeding. J Exp Med. 1988 Feb 1;167(2):440–451. doi: 10.1084/jem.167.2.440. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES